Vor Biopharma Inc.
VOR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing product candidates for cancer treatment, currently advancing a Phase 3 program after restructuring its operations and reducing its workforce in 2025.
Key risk: Clinical development uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.23B
Cash Runway
53.3 moLead Asset
telitacicept (Phase 3)Next Catalyst
Phase3_Topline · Jan 1, 2029Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials · 2 catalysts for Vor Biopharma Inc..
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing product candidates for cancer treatment, currently advancing a Phase 3 program after restructuring its operations and reducing its workforce in 2025.
- As of June 30, 2026, Vor Biopharma reported cash and equivalents of $107.9M and a net loss of -$62.8M for the quarter [sec].
- The company's accumulated deficit was $1,153.0M as of December 31, 2025 [sec_mda · as of 2026-03-30].
- In May 2025, Vor Biopharma approved a restructuring plan to wind down certain clinical and manufacturing operations, reducing its workforce by 154 full-time employees [sec_mda · as of 2026-03-30].
- Based on its current operating plan, the company expects its cash, cash equivalents, and marketable securities to fund operations into early 2029 [sec_mda · as of 2026-05-13].
- Vor Biopharma is conducting a Phase 3 study for its product candidate, with topline data expected around January 2029 [catalyst_timeline].
What works
- The company has a Phase 3 trial underway for its lead product candidate, indicating progress toward potential regulatory submission [catalyst_timeline].
- Management expects current cash resources to fund operations into early 2029, providing a multi-year runway for ongoing development [sec_mda · as of 2026-05-13].
What to weigh
- Vor Biopharma has an accumulated deficit of $1,153.0M as of December 31, 2025, reflecting significant historical losses [sec_mda · as of 2026-03-30].
- The company implemented a restructuring in May 2025 that included winding down operations and reducing its workforce by 154 employees, signaling a strategic pivot [sec_mda · as of 2026-03-30].
- Vor Biopharma is unable to predict when, if ever, material net cash inflows will commence from product sales, highlighting commercialization uncertainty [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Accumulated deficit as of December 31, 2025
“December 31, 2025, we had an accumulated deficit of $1,153.0 million.”
SEC MD&A · March 30, 2026
Restructuring plan approved in May 2025
“On May 5, 2025, our board of directors approved the wind down of our then-existing clinical and manufacturing operations focused on previous product candidates (the "Restructuring Plan").”
SEC MD&A · March 30, 2026
Workforce reduction of 154 employees
“In conjunction with the Restructuring Plan, we announced a reduction of our workforce by 154 full-ti”
SEC MD&A · March 30, 2026
Cash runway into early 2029
“cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into early 2029.”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2029-01-01 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy — Topline data from the Phase 3 study will provide efficacy and safety results for the lead product candidate.
- 2029-01-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to — Topline data from this Phase 3 study with an open-label extension will inform long-term treatment effects.
Risks & what to watch (3)›
Key risks
- Clinical development uncertainty — The timing and success of clinical trials are uncertain and subject to numerous risks outside the company's control [sec_mda · as of 2026-08-11].
- Going concern risk — If additional funding is not obtained, there can be no assurance the company will continue as a going concern [sec_mda · as of 2025-11-13].
- No product revenue — The company is unable to predict when material net cash inflows from product sales will commence, if ever [sec_mda · as of 2026-08-11].
What to watch
- Phase 3 topline data expected around January 2029 [catalyst_timeline].
- Cash burn rate and any additional financing activities given the $107.9M cash balance as of June 30, 2026 [sec].
- Progress of the restructuring plan and its impact on operating expenses and pipeline focus [sec_mda · as of 2026-03-30].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Vor Biopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vor Biopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
53.3 months
OCF -$25M · Net income -$63M
Lead: Phase 3
3 candidates
2 upcoming, next in ~855d
0 buys · 16 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
76
Total value held
$518.0M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 5,404,998 | $96.4M |
| fcpm iii services b.v. | 4,117,354 | $73.5M |
| vanguard capital management llc | 2,866,560 | $51.1M |
| caligan partners lp | 1,925,066 | $34.3M |
| great point partners llc | 1,750,000 | $31.2M |
| fmr llc | 1,539,670 | $27.5M |
| marshall wace, llp | 1,153,276 | $20.6M |
| state street corp | 1,118,458 | $20.0M |
| nextbio capital management lp | 999,967 | $17.8M |
| blackrock, inc. | 794,759 | $14.2M |
Showing top 10 of 76 institutional holders of Vor Biopharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 12.7%
- Days to cover
- 5.4
- Shares short
- 5,687,983
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vor Biopharma Inc.?
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing product candidates for cancer treatment, currently advancing a Phase 3 program after restructuring its operations and reducing its workforce in 2025.
What is Vor Biopharma Inc.'s lead drug candidate?
Vor Biopharma Inc.'s most advanced tracked candidate is telitacicept (Phase 3) for Generalized Myasthenia Gravis; Primary Sjogren's Disease.
What is Vor Biopharma Inc.'s next catalyst?
Vor Biopharma Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy " — expected January 1, 2029.
Who is the CEO of Vor Biopharma Inc.?
Dr. Jean-Paul Kress M.D. is the chief executive officer of Vor Biopharma Inc. (VOR).
Where is Vor Biopharma Inc. headquartered?
Vor Biopharma Inc. (VOR) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.